Machado Bruna Aparecida Souza, Hodel Katharine Valéria Saraiva, Fonseca Larissa Moraes Dos Santos, Pires Vinícius Couto, Mascarenhas Luis Alberto Brêda, da Silva Andrade Leone Peter Correia, Moret Marcelo Albano, Badaró Roberto
SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, Salvador 41650-010, Brazil.
UNEB, Universidade do Estado da Bahia, Salvador 41150-000, Brazil.
Vaccines (Basel). 2022 Apr 12;10(4):591. doi: 10.3390/vaccines10040591.
The COVID-19 pandemic has led the world to undertake the largest vaccination campaign in human history. In record time, unprecedented scientific and governmental efforts have resulted in the acquisition of immunizers utilizing different technologies (nucleotide acids, viral vectors, inactivated and protein-based vaccines). Currently, 33 vaccines have already been approved by regulatory agencies in different countries, and more than 10 billion doses have been administered worldwide. Despite the undeniable impact of vaccination on the control of the pandemic, the recurrent emergence of new variants of interest has raised new challenges. The recent viral mutations precede new outbreaks that rapidly spread at global proportions. In addition, reducing protective efficacy rates have been observed among the main authorized vaccines. Besides these issues, several other crucial issues for the appropriate combatting of the pandemic remain uncertain or under investigation. Particularly noteworthy issues include the use of vaccine-boosting strategies to increase protection; concerns related to the long-term safety of vaccines, child immunization reliability and uncommon adverse events; the persistence of the virus in society; and the transition from a pandemic to an endemic state. In this review, we describe the updated scenario regarding SARS-CoV-2 variants and COVID-19 vaccines. In addition, we outline current discussions covering COVID-19 vaccine safety and efficacy, and the future pandemic perspectives.
新冠疫情促使全球开展了人类历史上规模最大的疫苗接种运动。在创纪录的时间内,科学界和各国政府以前所未有的努力,研发出了采用不同技术(核酸、病毒载体、灭活和蛋白疫苗)的免疫制剂。目前,已有33种疫苗在不同国家获得监管机构批准,全球接种剂量已超过100亿剂。尽管疫苗接种对疫情防控产生了不可否认的影响,但新出现的值得关注的变异毒株不断涌现,带来了新的挑战。最近的病毒突变引发了新的疫情爆发,并迅速蔓延至全球范围。此外,主要授权疫苗的保护效力有所下降。除了这些问题,在抗击疫情的过程中,还有其他几个关键问题仍不明确或正在研究中。特别值得注意的问题包括采用加强免疫策略来增强保护效果;对疫苗长期安全性、儿童免疫可靠性和罕见不良事件的担忧;病毒在社会中的持续存在;以及从大流行向地方流行状态的转变。在这篇综述中,我们描述了关于新冠病毒变异毒株和新冠疫苗的最新情况。此外,我们概述了当前关于新冠疫苗安全性和有效性的讨论,以及未来疫情的展望。